Intravacc Launches Integrated Analytical Services to Accelerate Vaccine CMC Submissions and IND Readiness

For QA directors and regulatory affairs leads evaluating CDMO partnerships, Intravacc has formalised a commercial push around integrated analytical development services designed to reduce CMC submission risk and compress timelines from discovery to first-in-human studies. The Bilthoven-based CDMO announced the strategic emphasis on 8 June 2026.

Analytical characterisation sits at the centre of the offering. Before any candidate transitions to GMP manufacturing or clinical-phase work, developers must establish identity, potency, purity, structural integrity, formulation performance, and process consistency. Intravacc's service portfolio addresses each of these requirements across viral, bacterial, subunit, conjugate, protein-based, and therapeutic vaccine modalities.

The technical stack is broad. Identity and composition work relies on LC-MS-based methods capable of quantifying biologics in complex matrices. Purity assessment covers host-cell proteins, host-cell DNA, process-material residuals, degradation products, and endotoxins. Structural analysis extends to primary, secondary, and tertiary structure determination, post-translational modification identification, antigen binding and affinity measurement, and thermal stability evaluation. Formulation and stability activities include excipient and buffer screening, adjuvant and container compatibility assessment, and both real-time and accelerated stability studies.

Method development and validation round out the portfolio, targeting manufacturing consistency, product quality, and regulatory compliance. Read against the CMC documentation requirements embedded in ICH Q10 and the critical quality attribute framework that regulators expect at IND submission, the breadth of Intravacc's analytical scope positions the organisation to support partners through the full pre-clinical and early clinical data package.

CEO Ivo Lemmens stated that the objective is to reduce risk, strengthen CMC dossiers, and contribute to faster clinical entry for innovative vaccines. No specific partnership announcements or clinical programme timelines were disclosed alongside the service launch.

For regulatory affairs teams structuring CDMO agreements, the measurable checkpoint will be whether Intravacc's validated analytical methods transfer cleanly into the sponsor's IND-enabling study documentation and subsequent regulatory submissions.

Source: Intravacc via GlobeNewswire, 8 June 2026.